Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Clinical Trial
Share your love
Glaukos Secures FDA Approval for iDose TR
Glaukos has received FDA approval for iDose TR (travoprost intracameral implant 75 mcg), a groundbreaking prostaglandin analog intracameral implant designed to reduce intraocular pressure (IOP) in individuals with ocular hypertension or open-angle glaucoma. The iDose TR procedure, sanctioned for a…
FDA Approves Vuity for Twice-Daily Dosing in Presbyopia
AbbVie, the parent company of Allergan, has announced that the FDA has granted approval for the use of Vuity (pilocarpine HCl ophthalmic solution) 1.25% twice a day in adults suffering from presbyopia. The second dose, consisting of an additional drop…
2023 Recap: Top 15 Firsts in Ophthalmology
In a year marked by groundbreaking achievements, the field of ophthalmology witnessed a series of historic firsts, pushing the boundaries of innovation and patient care. Here are the noteworthy milestones: Pioneering the integration of technology into glaucoma management, the world’s…
Aviceda’s IND Cleared by FDA for GA to AMD Treatment
Aviceda Therapeutics announced that the FDA has granted clearance for the IND for AVD-104. This clearance will allow the company to proceed with the initiation of Phase 2 clinical trials of its leading intravitreal ocular asset for the treatment of…
FDA Calls for Study on Aldeyra’s Reproxalap in DED
Aldeyra Therapeutics announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) in response to the New Drug Application (NDA) for reproxalap, an investigational drug candidate designed for the treatment of dry eye disease.…
Reviving Hope for Amblyopia: Late-Stage Treatment
In children with amblyopia, often referred to as “lazy eye,” one eye exhibits weaker vision than the other due to various factors. This weaker eye may struggle with focusing, misalignment due to strabismus, or vision obstruction from conditions like cataracts…
UCL-Moorfields Eye Hospital Secures £5M for Research Center
The Sir Jules Thorn Charitable Trust has allocated £5 million towards the establishment of a research center within Oriel, the collaborative initiative between UCL and Moorfields Eye Hospital aimed at advancing eye health. Partnering with Moorfields Eye Charity and Moorfields…
New Experimental Drug Shows Promise in Treating DME
A recent study published in Nature Medicine has unveiled promising insights into a potential breakthrough in the treatment of Diabetic Macular Edema (DME). The study suggests that an experimental drug, part of a new class of therapeutics called “senolytics,” could…
Perfluorohexyloctane Drops Help Alleviate Dry Eye
According to recent research, perfluorohexyloctane eye drops (SHR8058) demonstrated significant improvement in both the signs and symptoms of dry eye disease (DED) linked to meibomian gland dysfunction (MGD) with rapid effectiveness in Chinese patients. The findings showed that the perfluorohexyloctane…
Treatment of Intraocular Melanoma | OBN
Melanoma of the uveal tract (iris, ciliary body, and choroid), though rare, is the most common primary intraocular malignancy in adults. The mean age-adjusted incidence of uveal melanoma in the United States is approximately 4.3 new cases per million people,…